Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01417052 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01417052: Completed Phase 1 study, sponsored by Lexicon Pharmaceuticals.
NCT01417052 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01417052, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety of LX3305 in a dose escalation compared with placebo over 12 weeks in subjects with active rheumatoid arthritis (RA).
Interventions
- DRUG 50 mg LX3305 QD
- DRUG 100 mg LX3305 QD
- DRUG 150 mg LX3305 QD
- DRUG 200 mg LX3305 QD
- DRUG 250 mg LX3305 QD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
What the finished NCT01417052 record still lists
NCT01417052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 5 interventions - of which 50 mg LX3305 QD is the first listed.
NCT01417052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01417052 about?
NCT01417052 is a clinical study titled "A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis". The primary objective of this study is to determine the safety of LX3305 in a dose escalation compared with placebo over 12 weeks in subjects with active rheumatoid arthritis (RA).
What is the current status of trial NCT01417052?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2011-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01417052?
The interventions under investigation include: 50 mg LX3305 QD (DRUG), 100 mg LX3305 QD (DRUG), 150 mg LX3305 QD (DRUG), 200 mg LX3305 QD (DRUG), 250 mg LX3305 QD (DRUG).
Who is sponsoring clinical trial NCT01417052?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01417052's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia